

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	Unassigned
Filing Date	June 23, 2005
First Named Inventor	Steffen GOLETZ et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	GULDE-63

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
/AMG/	1	2002132771			September 19, 2002

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/AMG/	2	WO	0244217		LO BENNY KWAN CHING	June 6, 2002		
/AMG/	3	WO	0112217		ALTAREX INC.	February 22, 2001		Equv to cite 1

Examiner
Signature

/Anne Gussow/

Date
Considered

06/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/540479

JC09 Rec'd PCT/PTO 28 JUN 2005

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	Unassigned
Filing Date	June 23, 2005
First Named Inventor	Steffen GOLETZ et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	GULDE-63

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/	4	PRICE M ET AL: "SUMMARY REPORT ON THE ISOBM TD-4 WORKSHOP: ANALYSIS OF 56 MONOCLONAL ANTIBODIES AGAINST THE MUC1 MUCIN" TUMOR BIOLOGY, KARGER, BASEL, CH, VOL. 19, NO. SUPPL 1, DECEMBER 1998 (1998-12), PAGES 1-20, XP002112482	
/AMG/	5	GOLETZ S ET AL: "BINDING PATTERNS OF 33 TD-4(MUC1) ANTIBODIES TOWARDS SINGLE-CHAIN FRAGMENTS AND PEPTIDES MIMICKING THE CONFORMATION OF THE MUC1 PDTRP EPI TOPE" TUMOR BIOLOGY, VOL. 21, NO. SUPPLEMENT 1, SEPTEMBER 2000 (2000-09), PAGE 142, XP008034905 & 28 TH MEETING OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE; MUNICH, GERMANY; SEPTEMBER 08-13, 2000.	

Examiner
Signature

/Anne Gussow/

Date
Considered

06/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/540,479
Filing Date	June 23, 2005
First Named Inventor	Steffen GOLETZ et al.
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	GULDE-0063

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Anne Gussow/

Date Considered

06/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/540,479
Filing Date	June 23, 2005
First Named Inventor	Steffen GOLETZ et al.
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	GULDE-0063

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T. ²
/AMG/	C1	BOEL, E. et al., "Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments," Journal of Immunological Methods, 2000, vol. 239, pgs. 153-166.	
	C2	BRECHBIEL, M.W. et al., "Synthesis on 1-(p-Isothiocyanatobenzyl) derivatives of DTPA and EDTA: Antibody labeling and tumor-imaging studies," Inorg. Chem., 1986, vol. 25, pgs. 2772-2781.	
	C3	CHOTHIA, C. et al., "The predicated structure of immunoglobulin D1.3 and its comparison with the crystal structure," Science Reports, 15 Aug. 1986, vol. 233, pgs. 755-758.	
	C4	CHOTHIA, C. et al., "Conformations of immunoglobulin hypervariable regions," Nature, 21/28 Dec. 1989, vol. 342, pgs. 877-883.	
	C5	CHOTHIA, C. et al., "Structural repertoire of the human Vh segments," Journal of Molecular Biology, 1992, vol. 227, pgs. 799-817.	
	C6	CHOTHIA, C. et al., "Canonical structures for the hypervariable regions of immunoglobulins," Journal of Molecular Biology, 1987, vol. 196, pgs. 901-917.	
	C7	HERRERA, A.M. et al., "Efficiency of erythropoietin's signal peptide for HIVmn-1 gp 120 expression," Biochemical and Biophysical Research Communications, 2000, vol. 273, pgs. 557-559.	
	C8	DAI, J. et al., "Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin," Tumor Biology, 1998, vol. 19 supp. 1, pgs. 100-110.	
	C9	HINODA, Y. et al., "Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin: comparison of antigen MUSE11 with CA15-3," Gastroenterologia Japonica, 1992, vol. 27 no. 3, pgs. 390-395.	
	C10	JENSEN, K.B. et al., "Functional improvement of antibody fragments using a novel phage coat protein III fusion system," Biochemical and Biophysical Research Communications, 2002, vol. 298, pgs. 566-573.	
/AMG/	C11	KOZAK, R.W. et al., "Nature of the Bifunctional chelating agent used for radioimmunotherapy with Yttrium-90 monoclonal antibodies: Critical factors in determining 'in vivo' survival and organ toxicity," Cancer Research, 15 May 1989, vol. 49, pgs. 2639-2644.	

Examiner
Signature

/Anne Gussow/

Date
Considered

06/12/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type or print inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete If Known

Application Number	10/540,479
Filing Date	June 23, 2005
First Named Inventor	Steffen GOLETZ et al.
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	GULDE-0063

NON PATENT LITERATURE DOCUMENTS (continued)			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/	C12	LIAO, K. et al., "Design of transgenes for efficient expression of active chimeric proteins on mammalian cells," Biotechnol. Bioeng., 2000, vol. 73, pgs. 313-323.	
	C13	MARTIN, A.C.R. et al., "Structural families in loops of homologous proteins: Automatic classification, modeling and application to antibodies," Journal of Molecular Biology, 1996, vol. 263, pgs. 800-815.	
	C14	NUTTALL, S.D. et al., "Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides," Proteins: Structure, Function, and Genetics, 1999, vol. 36, pgs. 217-227.	
	C15	NYGREN, P. et al., "Scaffolds for engineering novel binding sites in proteins," Cur. Opin. Struc. Biol., 1997, vol. 7, pgs. 463-469/	
	C16	ROOMAN, M.J. et al., "Amino acid sequence templates derived from recurrent turn motifs in proteins: critical evaluation of their predictive power," Protein Engineering, 1989, vol. 3 no. 1, pgs. 23-27.	
	C17	SKERRA, A., "Engineered protein scaffolds for molecular recognition," Journal of Molecular Recognition, 2000, vol. 13, pgs. 167-187.	
	C18	STIMMEL, J.B. et al., "Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator," Bioconjugate Chemistry, 1995, vol. 6, pgs. 219-225.	
	C19	TONYE LIBYH, M. et al., "A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein," Blood, 15 Nov. 1997, vol. 90 no. 10, pgs. 3978-3983.	
/AMG/	C20	WU, S. et al., "Conformation of complementarity determining region L1 loop in murine IgG λ light chain extends the repertoire of canonical forms," Journal of Molecular Biology, 1993, vol. 229, pgs. 597-601.	

Examiner
Signature

/Anne Gussow/

Date
Considered

06/12/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.